All In MedTech

Device Trial Radar · NCT04592445

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 18, 2020

Primary completion

Jan 10, 2028

Study completion Aug 10, 2029

Sponsor

Lead sponsor
Axon Therapies, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
NAMSA; Cardiovascular Research Foundation, New York; Northwestern University
First posted
Oct 19, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFpEF

Interventions

  • Greater Splanchnic Nerve AblationDevice

    The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.

  • Sham ControlDevice

    During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint: Device or procedure related serious adverse eventsTime frame: 1 Month
  2. Primary Efficacy Endpoint: KCCQ (6 months)Time frame: Baseline through 6-months
  3. Primary Efficacy Endpoint: 6MWT (6 months)Time frame: Baseline through 6 months

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Cardiology PC

    Birmingham, Alabama · Completed

  • Arizona Cardiovascular Research Center

    Phoenix, Arizona · Completed

  • Scripps Health

    La Jolla, California · Recruiting

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.